Cantor Fitzgerald Initiates $TEM at Overweight, PT $80 Analyst comments: "TEM is an AI-powered precision medicine data company with most of its upside coming from a single correction: The Street values Data & Applications like a life sciences data vendor, although its growth and margins more closely resemble a platform business. Combined with diversified exposure to biopharma R&D and provider adoption, as well as five under-appreciated growth levers, we believe the risk/reward skews heavily to the upside. Tempus’ D&A segment is mispriced against the wrong peer group, in our view. While Dx trades in-line with its true peer group (6.6x 2028 EV/Revenue, per BLLN, CAI, GH, NTRA, and NEO), D&A does not. The market prices its 26% growth and 76% gross margin off decelerating staffing and hardware-heavy data-vendor peers (IQV, VEEV, TXG, and CERT at 6.1x) instead of the platform businesses whose growth and margin profile it actually matches (PLTR, SNOW, DDOG, and RDDT at 11.7x)." Analyst: Sarah James